These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunotherapy for Alzheimer's disease. Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646 [TBL] [Abstract][Full Text] [Related]
4. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice. Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784 [TBL] [Abstract][Full Text] [Related]
5. Alzheimer disease. Could anti-amyloid-β immunotherapy do more harm than good? Wood H Nat Rev Neurol; 2016 Jan; 12(1):2. PubMed ID: 26610710 [No Abstract] [Full Text] [Related]
6. [Current trend of immunotherapy for Alzheimer's disease]. Matsumoto SE; Tabira T Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. Wilcock DM; Colton CA CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):50-64. PubMed ID: 19275636 [TBL] [Abstract][Full Text] [Related]
11. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease? Panza F; Lozupone M; Dibello V; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP Immunotherapy; 2019 Jan; 11(1):3-6. PubMed ID: 30702009 [No Abstract] [Full Text] [Related]
12. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Nitsch RM; Hock C Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453 [TBL] [Abstract][Full Text] [Related]
13. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease. Murakami K Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729 [TBL] [Abstract][Full Text] [Related]
14. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I. Agadjanyan MG; Cribbs DH CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):1-6. PubMed ID: 19275632 [No Abstract] [Full Text] [Related]
16. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Fukuchi K; Tahara K; Kim HD; Maxwell JA; Lewis TL; Accavitti-Loper MA; Kim H; Ponnazhagan S; Lalonde R Neurobiol Dis; 2006 Sep; 23(3):502-11. PubMed ID: 16766200 [TBL] [Abstract][Full Text] [Related]
17. Treatment of Alzheimer's disease: the beginning of a new era. Schenk D Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091 [No Abstract] [Full Text] [Related]